Purpose. To evaluate the willingness to trade survival to avoid the side effects of long-term androgen deprivation (LTAD) versus short-term androgen deprivation (STAD) in prostate cancer survivors.Methods and materials. Patients who had received radiotherapy for prostate cancer were presented with a scenario of Locally Advanced Prostate Cancer. We determined the minimally required increment in survival (MRIS) to accept LTAD (as opposed to STAD), using the Probability trade-off technique. Utilities for impotence and osteoporosis were determined using the Time trade-off technique.Results. Sixty-seven patients were interviewed. All participants were willing to trade survival in order not to have to undergo LTAD, compared to STAD. The median MRIS for prostate cancer-specific survival was 9.5%. The median utility for impotence was 0.84. Median utility for osteoporosis was 0.72.